Only 1 in 3 Older Adults Screened for Cannabis, Drug Use
✦ New CED Clinical Relevance #52 Clinical Context Background information relevant to the evolving cannabis medicine landscape. AgingResearchSafetyPolicyMental HealthAnxietyPain Why This Matters Clinicians miss opportunities to identify substance…
Cannabis caution as study finds increased psychosis risk for young people
✦ New CED Clinical Relevance #47 Clinical Context Background information relevant to the evolving cannabis medicine landscape. Mental HealthResearchSafetyTHCPediatricsAnxietyNeurology Why This Matters Clinicians treating young patients must weigh…
7 unexpected takeaways from the newest research on cannabis and brain effects
✦ New CED Clinical Relevance #47 Clinical Context Background information relevant to the evolving cannabis medicine landscape. ResearchMental HealthNeurologyTHCCBDSafetyPolicy Clinical Summary Recent research on cannabis and neurobiological…
One Scientist’s War To Understand Unregulated Drugs
✦ New CED Clinical Relevance #67 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ResearchHempSafetyPolicyIndustryPainAnxiety Why This Matters Clinicians need standardized cannabis testing data to…
When Back Pain Becomes Chronic: New Drug and Old-Fashioned Remedies Hold Promise
The standardized cannabis pharmaceutical offers a new regulated option for chronic back pain management. This product provides consistent dosing and quality control compared to herbal cannabis. It represents a promising alternative for patients with…
Headed to a New York Dispensary This Weekend? Silly Nice Launches Concentrate Education Hub
✦ New CED Clinical Relevance #77 Strong Clinical Relevance High-quality evidence with meaningful patient or clinical significance. THCIndustrySafetyDosingResearchHempCBD Why This Matters Clinicians should understand cannabis concentrate potency…
Schedules of Controlled Substances: Temporary Placement of 2-Fluorodeschloroketamine in Schedule I
The DEA emergency scheduling controlled substances update includes the temporary placement of 2-fluorodeschloroketamine in Schedule I. This reflects regulatory efforts to address emerging synthetic drugs with abuse potential. Clinicians should monitor…
In the Mix: 7 More Articles — June 18, 2026
This post reviews cannabis clinical relevance articles June 18 2026, highlighting recent studies and regulatory updates. The articles provide valuable insights into cannabis research and clinical implications. Stay informed on the latest developments in…
Schedules of Controlled Substances: Placement of Clonazolam, Diclazepam, Etizolam, Flualprazolam, and Flubromazolam in Schedule I
The DEA scheduling benzodiazepine analogs in Schedule I addresses the abuse potential of synthetic benzodiazepines. These substances pose significant clinical risks and regulatory challenges. Clinicians should be vigilant for exposure to these…
Temporary Scheduling of Bromazolam and Novel Benzodiazepines
The temporary scheduling of novel benzodiazepines such as bromazolam reflects regulatory efforts to address emerging abuse risks. This update highlights clinical toxicology concerns and enforcement under the Controlled Substances Act. Clinicians should…